AnteoTech Limited, a surface chemistry company, develops, commercializes, manufactures, and distributes products for the life sciences, diagnostics, energy, and medical device markets primarily in Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.25|
|52 Week High||AU$0.077|
|52 Week Low||AU$0.49|
|1 Month Change||-7.41%|
|3 Month Change||11.11%|
|1 Year Change||127.27%|
|3 Year Change||1,462.70%|
|5 Year Change||354.55%|
|Change since IPO||-10.71%|
Recent News & Updates
We Think AnteoTech (ASX:ADO) Can Easily Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, AnteoTech ( ASX:ADO...
|ADO||AU Life Sciences||AU Market|
Return vs Industry: ADO exceeded the Australian Life Sciences industry which returned 5.8% over the past year.
Return vs Market: ADO exceeded the Australian Market which returned 21.4% over the past year.
Stable Share Price: ADO is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: ADO's weekly volatility has decreased from 20% to 15% over the past year, but is still higher than 75% of Australian stocks.
About the Company
AnteoTech Limited, a surface chemistry company, develops, commercializes, manufactures, and distributes products for the life sciences, diagnostics, energy, and medical device markets primarily in Australia. The company’s products include AnteoCoat, which comprise a suite of compounds that enable the control of material interactions and properties in the energy storage applications; AnteoBind ready-to-use kits to streamline and improve the conjugation process; and EuGeni, a COVID-19 antigen rapid test. It has collaboration agreements with Axxin for COVID-19 anigen test.
AnteoTech Fundamentals Summary
|ADO fundamental statistics|
Is ADO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ADO income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0032|
|Net Profit Margin||-270.33%|
How did ADO perform over the long term?See historical performance and comparison
Is AnteoTech undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ADO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ADO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ADO is unprofitable, so we can't compare its PE Ratio to the Global Life Sciences industry average.
PE vs Market: ADO is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ADO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ADO is overvalued based on its PB Ratio (23.3x) compared to the AU Life Sciences industry average (5.2x).
How is AnteoTech forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ADO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: ADO is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ADO's is expected to become profitable in the next 3 years.
Revenue vs Market: ADO's revenue (49.6% per year) is forecast to grow faster than the Australian market (5.3% per year).
High Growth Revenue: ADO's revenue (49.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ADO's Return on Equity is forecast to be very high in 3 years time (69%).
How has AnteoTech performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ADO is currently unprofitable.
Growing Profit Margin: ADO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ADO is unprofitable, but has reduced losses over the past 5 years at a rate of 17.2% per year.
Accelerating Growth: Unable to compare ADO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ADO is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (59.8%).
Return on Equity
High ROE: ADO has a negative Return on Equity (-29.44%), as it is currently unprofitable.
How is AnteoTech's financial position?
Financial Position Analysis
Short Term Liabilities: ADO's short term assets (A$21.8M) exceed its short term liabilities (A$1.1M).
Long Term Liabilities: ADO's short term assets (A$21.8M) exceed its long term liabilities (A$1.5M).
Debt to Equity History and Analysis
Debt Level: ADO is debt free.
Reducing Debt: ADO has no debt compared to 5 years ago when its debt to equity ratio was 20.8%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ADO has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ADO has sufficient cash runway for 3 years if free cash flow continues to grow at historical rates of 15.6% each year.
What is AnteoTech current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ADO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ADO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ADO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ADO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ADO's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Derek Thomson serves as Chief Executive Officer at AnteoTech Limited (formerly known as Anteo Diagnostics Limited) since August 8, 2019. He is an accomplished executive and has held senior roles with p...
CEO Compensation Analysis
Compensation vs Market: Derek's total compensation ($USD327.95K) is below average for companies of similar size in the Australian market ($USD716.52K).
Compensation vs Earnings: Derek's compensation has increased whilst the company is unprofitable.
Experienced Management: ADO's management team is considered experienced (2.5 years average tenure).
Experienced Board: ADO's board of directors are not considered experienced ( 0.1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ADO insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.7%.
AnteoTech Limited's employee growth, exchange listings and data sources
- Name: AnteoTech Limited
- Ticker: ADO
- Exchange: ASX
- Founded: 1995
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$492.598m
- Shares outstanding: 1.97b
- Website: https://www.anteotech.com
Number of Employees
- AnteoTech Limited
- Brisbane Technology Park
- Unit 4
- Eight Mile Plains
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/22 15:37|
|End of Day Share Price||2021/10/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.